https://pharmato.ai 2026-04-11T21:15:47.138Z https://pharmato.ai/blog 2026-04-11T21:15:47.138Z https://pharmato.ai/pricing 2026-04-11T21:15:47.138Z https://pharmato.ai/consulting 2026-04-11T21:15:47.138Z https://pharmato.ai/calendar 2026-04-11T21:15:47.138Z https://pharmato.ai/blog/summary-of-the-phase-1b2-study-of-9mw2821-combined-with-toripalimab-in-treatment-naive-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma 2026-04-10T08:13:00.000Z https://pharmato.ai/blog/exploratory-analysis-of-responders-from-the-phase-3-ev-302-trial 2026-04-10T07:00:00.000Z https://pharmato.ai/blog/immunotherapy-adc-breakthrough-in-advanced-urothelial-carcinoma-in-depth-analysis-of-the-javelin-bladder-medley-phase-2-interim-results 2026-04-10T04:01:00.000Z https://pharmato.ai/blog/final-results-of-the-checkmate-901-trial-efficacy-of-nivolumab-plus-ipilimumab-in-cisplatin-ineligible-advanced-urothelial-carcinoma 2026-04-10T03:25:00.000Z https://pharmato.ai/blog/phase-1-study-of-b440-an-oral-bifidobacterium-engineered-wt1-cancer-vaccine-in-patients-with-metastatic-urothelial-cancer 2026-04-10T03:14:00.000Z https://pharmato.ai/blog/enlighted-phase-3-study-interim-results-of-efficacy-and-safety-of-padeliporfin-vascular-targeted-photodynamic-therapy-vtp-in-lg-utuc 2026-04-10T03:01:00.000Z https://pharmato.ai/blog/pharmato-upgrades-ai-knowledge-base 2026-04-08T14:57:00.000Z https://pharmato.ai/blog/amgen-phase-3-trial-of-subcutaneous-teprotumumab-for-thyroid-eye-disease-shows-positive-results-with-proptosis-response-rate-up-to-77 2026-04-07T05:56:00.000Z https://pharmato.ai/blog/oral-glp-1-clinical-comparison-novo-nordisks-oral-semaglutide-vs-eli-lillys-orforglipron 2026-04-05T05:42:00.000Z https://pharmato.ai/blog/poster-cr5-inhibition-with-the-human-monoclonal-antibody-leronlimab-enhances-temozolomide-and-radiation-induced-killing-of-glioblastoma-multiforme-cells 2026-04-02T10:02:00.000Z https://pharmato.ai/blog/united-therapeutics-breakthrough-phase-3-results-of-tyvaso-in-idiopathic-pulmonary-fibrosis 2026-03-31T09:35:00.000Z https://pharmato.ai/blog/biogen-litifilimab-phase-2-trial-meets-primary-endpoint-in-cutaneous-lupus-erythematosus 2026-03-30T14:31:00.000Z https://pharmato.ai/blog/rocket-pharmaceuticals-rcktnasdaq-approaches-pdufa-decision-for-kresladi 2026-03-26T14:39:00.000Z https://pharmato.ai/blog/pharmato-integras-free-access-boost-new-drug-intelligence-efficiency-by-10x 2026-03-26T13:12:00.000Z https://pharmato.ai/blog/efficiently-building-a-competitive-intelligence-landscape-for-new-drug-pipelines 2026-03-26T13:04:00.000Z https://pharmato.ai/blog/shionogi-buys-out-joint-venture-for-150-million-to-tap-into-the-10-billion-osa-blue-ocean-market 2026-03-26T13:01:00.000Z https://pharmato.ai/blog/sanofi-returns-to-tce-arena-with-123b-acquires-kalis-trispecific-antibody-kt501-1 2026-03-26T13:01:00.000Z https://pharmato.ai/blog/united-therapeutics-ralinepag-achieves-phase-3-success-in-pulmonary-arterial-hypertension 2026-03-03T08:21:00.000Z